X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dishman Pharma with SUVEN LIFE - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs SUVEN LIFE - Comparison Results

DISHMAN PHARMA    Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA SUVEN LIFE DISHMAN PHARMA/
SUVEN LIFE
 
P/E (TTM) x 25.1 19.2 131.0% View Chart
P/BV x 3.3 3.6 94.2% View Chart
Dividend Yield % 0.7 1.1 63.0%  

Financials

 DISHMAN PHARMA   SUVEN LIFE
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
SUVEN LIFE
Mar-16
DISHMAN PHARMA/
SUVEN LIFE
5-Yr Chart
Click to enlarge
High Rs374339 110.6%   
Low Rs129144 89.3%   
Sales per share (Unadj.) Rs197.839.2 504.0%  
Earnings per share (Unadj.) Rs21.27.5 284.2%  
Cash flow per share (Unadj.) Rs34.78.8 395.7%  
Dividends per share (Unadj.) Rs2.002.00 100.0%  
Dividend yield (eoy) %0.80.8 95.9%  
Book value per share (Unadj.) Rs179.949.0 367.1%  
Shares outstanding (eoy) m80.69127.28 63.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.36.2 20.7%   
Avg P/E ratio x11.932.4 36.7%  
P/CF ratio (eoy) x7.227.5 26.3%  
Price / Book Value ratio x1.44.9 28.4%  
Dividend payout %9.426.8 35.2%   
Avg Mkt Cap Rs m20,30630,732 66.1%   
No. of employees `0000.81.0 86.9%   
Total wages/salary Rs m5,355416 1,286.0%   
Avg. sales/employee Rs Th19,252.75,236.1 367.7%   
Avg. wages/employee Rs Th6,459.5436.5 1,479.9%   
Avg. net profit/employee Rs Th2,064.1995.5 207.3%   
INCOME DATA
Net Sales Rs m15,9614,995 319.5%  
Other income Rs m265194 137.2%   
Total revenues Rs m16,2265,189 312.7%   
Gross profit Rs m4,1031,233 332.9%  
Depreciation Rs m1,091167 652.3%   
Interest Rs m94454 1,742.4%   
Profit before tax Rs m2,3341,205 193.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m624255 244.5%   
Profit after tax Rs m1,711950 180.2%  
Gross profit margin %25.724.7 104.2%  
Effective tax rate %26.721.2 126.2%   
Net profit margin %10.719.0 56.4%  
BALANCE SHEET DATA
Current assets Rs m11,0184,986 221.0%   
Current liabilities Rs m9,5171,042 913.1%   
Net working cap to sales %9.479.0 11.9%  
Current ratio x1.24.8 24.2%  
Inventory Days Days11061 181.2%  
Debtors Days Days3539 89.0%  
Net fixed assets Rs m16,3043,126 521.6%   
Share capital Rs m161127 126.8%   
"Free" reserves Rs m12,9073,717 347.2%   
Net worth Rs m14,5166,236 232.8%   
Long term debt Rs m4,189432 969.1%   
Total assets Rs m29,8058,079 368.9%  
Interest coverage x3.523.2 14.9%   
Debt to equity ratio x0.30.1 416.4%  
Sales to assets ratio x0.50.6 86.6%   
Return on assets %8.912.4 71.7%  
Return on equity %11.815.2 77.4%  
Return on capital %17.518.9 92.9%  
Exports to sales %24.887.5 28.3%   
Imports to sales %3.712.2 30.6%   
Exports (fob) Rs m3,9564,371 90.5%   
Imports (cif) Rs m596611 97.6%   
Fx inflow Rs m4,9524,666 106.1%   
Fx outflow Rs m697942 74.0%   
Net fx Rs m4,2553,724 114.2%   
CASH FLOW
From Operations Rs m2,786922 302.2%  
From Investments Rs m-1,529-619 246.9%  
From Financial Activity Rs m-941-698 134.8%  
Net Cashflow Rs m316-396 -80.0%  

Share Holding

Indian Promoters % 61.4 63.4 96.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 0.0 -  
FIIs % 12.7 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 36.5 60.5%  
Shareholders   46,261 37,287 124.1%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   FDC LTD.  UNICHEM LAB  WYETH LTD  AJANTA PHARMA  ALEMBIC LTD  

Compare DISHMAN PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views on News

Suven Lifesciences: Profits Decline due to Higher tax outgo in the quarter (Quarterly Results Update - Detailed)

Sep 22, 2017

Muted growth in CRAMS segment continues to impact topline.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 8-QTR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS